ArticleJournal of translational medicine2026
The impact of hypoxia and glycolysis on liver fibrosis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
methodsHypoxia, glycolysis, and lactylation are key processes in liver fibrosis (LF) and hepatocarcinogenesis, yet the role of hypoxia-, glycolysis-, and lactylation-related genes (HGLRGs) in LF is poorly defined. Here, we systematically analyzed transcriptomic data from LF samples to identify differentially expressed HGLRGs, validate by single-cell transcriptomics, construct co-expression networks, evaluate their biological functions, diagnostic performance, immune relevance, and explore potential therapeutic agents.
resultsSeven HGLRGs-CHST4, FABP5, GPC3, SOX9, SRPX, IFI16, and ISG20-were significantly upregulated in LF and demonstrated strong diagnostic value. FABP5 and ISG20 were consistently elevated in activated stellate cells and human cirrhotic livers. Enrichment analyses indicated that these genes modulate metabolic pathways and drive immune-mediated fibrotic responses. Immune profiling revealed that ISG20 expression inversely correlated with resting NK cell infiltration, and SOX9 with M2 macrophage infiltration. Molecular docking identified seven FDA-approved drugs, including aspirin, Methylene blue, tamoxifen, vorinostat, valproic acid, rosiglitazone and acetaminophen, as potential HGLRG-targeting agents.
conclusionHGLRGs are aberrantly upregulated and actively contribute to LF progression through metabolic dysregulation and immune remodeling. FABP5 and ISG20 represents promising biomarkers and therapeutic target. This study providing novel diagnostic markers, drug repurposing opportunities, and strategies for improved clinical management of liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.